Supernus Pharma's ADHD treatment fails to impress; shares fall

Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news